The Wall Street Journal is reporting that the Trump Administration is considering a major change to patent fees, which would ...

Commerce Department officials are discussing a new fee based on patent value, which could fuel backlash from businesses.

Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of recent court rulings following Amgen v. Sanofi on broad genus claims within life ...